Exo acquires Medo AI to improve ultrasound imaging

Redwood City, California-based Exo intends to integrate Medo's proprietary Sweep AI technology into its ultrasound platform to make the imaging modality more accessible to a wider range of caregivers. No financial terms for the acquisition were disclosed. According to a news release, Canada-based Medo's ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, giving non-experts the ability to conduct high-quality exams quickly and accurately. The company brings with it two FDA-cleared AI algorithms, as well as more in development, plus access to an extensive library of millions of ultrasound images and longitudinal health data to speed up point-of-care ultrasound adoption across the healthcare system, potentially expanding early disease detection and accelerating the path to treatment. Medo also holds strong partnerships across health systems worldwide, Exo said, including top institutions in Asia and Canada that can help to enable clinical validation and adoption.